May 4, 2026
FDA Rejects Promising Melanoma Drug RP1 Twice, Raising Concerns About Drug Approval Process
The FDA has rejected RP1, a breakthrough melanoma treatment, twice despite its promise in treating skin cancer. The rejections have left medical professionals puzzled and concerned about implications for future drug approvals.
1 source
00